^
    12h
    Venetoclax and Decitabine in R/R T-ALL (clinicaltrials.gov)
    P2, N=28, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Venclexta (venetoclax) • decitabine
    15h
    Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (clinicaltrials.gov)
    P1, N=5, Completed, Dana-Farber Cancer Institute | Trial completion date: Feb 2026 --> Apr 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    Venclexta (venetoclax)
    3d
    C1orf35 contributes to high anabolic metabolism by simultaneously promoting aerobic glycolysis and oxidative phosphorylation in multiple myeloma cells. (PubMed, Cancer Gene Ther)
    Our study uncovers a "C1orf35-driven" energy metabolism model in MM cells, providing new insights into the pathogenesis of MM and a potential novel target for the treatment of cancer cells with a high"C1orf35-driven" anabolic metabolism. Schematic diagram of C1orf35 simultaneously promotes glycolysis and OXPHOS.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PKM (Pyruvate Kinase M1/2) • LRPPRC (Leucine Rich Pentatricopeptide Repeat Containing)
    |
    R-(-)-gossypol (AT 101)
    3d
    μPharma: A microfluidic, AI-driven pharmacotyping platform for single-cell drug sensitivity prediction in leukemia. (PubMed, Med)
    μPharma provides rapid (4-h assay), accurate, and automated prediction of drug sensitivity at single-cell resolution using minimal clinical samples, potentially enabling same-day precision oncology decision-making.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • dasatinib
    3d
    A Prospective, Single-Arm, Multicenter Study on the Efficacy and Safety of Lisaftoclax Combined with Rituximab and Lenalidomide Regimen in the Treatment of Previously Untreated Elderly Patients with Mantle Cell Lymphoma (ChiCTR2500115112)
    P=N/A, N=40, Not yet recruiting, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University; Jiangsu Province Hospital, The First Affiliated Hospital of Na
    New trial
    |
    Rituxan (rituximab) • lenalidomide • lisaftoclax (APG-2575)
    3d
    A prospective, single-arm, multicenter clinical study of a maintenance regimen comprising Venetoclax combined with Azacitidine for adult patients with newly diagnosed acute myeloid leukemia (non-APL) who have achieved remission following standard induction and consolidation chemotherapy (ChiCTR2500114099)
    P=N/A, N=80, Not yet recruiting, Mianyang Central Hospital; Mianyang Central Hospital
    New trial
    |
    Venclexta (venetoclax) • azacitidine
    3d
    A prospective, multicenter, single-arm clinical study of low-dose Decitabine combined with Venetoclax in the treatment of newly diagnosed high-risk myelodysplastic syndrome patients. (ChiCTR2500114059)
    P=N/A, N=52, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.; Institute of Hematolog
    New trial
    |
    Venclexta (venetoclax) • decitabine
    3d
    Gilteritinib plus venetoclax and azacitidine in FLT3-mutated acute myeloid leukemia: a multicenter retrospective cohort study (ChiCTR2500112896)
    P=N/A, N=111, Completed, The first affiliated hospital, Zhejiang University School of Medicine; The first affiliated hospital, Zhejiang University School of Medicine
    New trial
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3-ITD mutation • FLT3 mutation
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine
    3d
    Sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia: a prospective, single-arm, multicenter clinical study (ChiCTR2500112555)
    P=N/A, N=87, Not yet recruiting, Nanfang Hospital, Southern Medical University; Nanfang Hospital, Southern Medical University
    New trial
    |
    Venclexta (venetoclax) • sorafenib
    3d
    Clinical Study on Efficacy and Safety of G-CSF Combined with Azacitidine and Venetoclax in the Treatment of Adult Acute Myeloid Leukemia (ChiCTR2500112100)
    P=N/A, N=34, Not yet recruiting, The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • lisaftoclax (APG-2575)
    3d
    Efficacy and safety of sequential therapy with Venetoclax, Azacitidine, and Homoharringtonine in elderly patients with de novo AML: A prospective, single-arm, multicenter, exploratory clinical trial (ChiCTR2500112019)
    P=N/A, N=40, Not yet recruiting, the First Affiliated Hospital, Zhejiang University School of Medicine; The People's Hospital Affiliated to Ningbo University
    New trial
    |
    Venclexta (venetoclax) • azacitidine • Synribo (omacetaxine mepesuccinate)
    3d
    An Open-Label, Single-Arm Study of Sonrotoclax Plus Zanubrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without Disease Progression After First-Line BTK Inhibitor Therapy. (ChiCTR2500111878)
    P=N/A, N=50, Not yet recruiting, The First Affiliated Hospital of Soochow University; The First Affiliated Hospital of Soochow University
    New trial
    |
    Brukinsa (zanubrutinib) • sonrotoclax (BGB-11417)